Novo Nordisk, a Danish pharmaceutical company, has announced a $556 million investment in a sterile preparations expansion project at its facility in Tianjin, China.   The new facility will use isolator technology to improve sterility and meet the increasing demands of the Chinese market for Novo’s therapies. The project is expected to be completed by 2027 and will support localized drug production while boosting the company’s production capacity.   Novo’s Tianjin plant, wh...